Middletown, DE -- (SBWIRE) -- 10/04/2013 -- VipStockReports.com screens the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way. Today our focus is on: Avanir Pharmaceuticals Inc(NASDAQ:AVNR), Antares Pharma Inc(NASDAQ:ATRS), Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX), Exelixis, Inc.(NASDAQ:EXEL)
Avanir Pharmaceuticals Inc(NASDAQ:AVNR) was a volume gainer of 2.11 million shares and the average volume of the stock remained 4.04 million shares. The stock opened the session at $4.54 and finished at the end of the day at $4.34 and the stock plunged -4.19% .The market capitalizations of the stock remained 631.34 million. The half-yearly trend of the stock remained positive +61.94%. Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.
Has AVNR Found The Bottom And Ready To Gain Momentum? Find Out Here
In the preceding trading session, Antares Pharma Inc(NASDAQ:ATRS) exchanged 2.09 million shares and the average volume remained 1.16 million shares. The stock closed the session at $4.45 with the gain of +4.09%. Tracking three months and 6 months trends, the stock was at of +4.22% and +27.14%, respectively. Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies, and topical gel-based medicines worldwide.
Will ATRS Continue To Move Higher? Find Out Here
Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX) decreased -2.75% and its closing price was $2.83. The volume of the stock was 2.09 million shares and the average volume remained 1.52 million shares. Yesterday, the stock traded amid the day price range of $2.75 - $2.92. The market capitalization of the stock remained 1.45 billion. The beta of the stock remained 1.73. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes.
Will LXRX Get Buyers Even After The Recent Rally? Find Out Here
Exelixis, Inc.(NASDAQ:EXEL) exchanged 2.03 million shares in the previous trading session, and its average trading remained 2.03 million shares. EXEL dropped -2.38% and it closed the trading at $5.75. The market capitalization of the stock remained 1.06 billion. YTD trend of the stock was positive +27.49%. Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer.
Has EXEL Found The Bottom and Ready To Move Up? Find Out Here
We screen the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Once we find the 'Next Hot Penny Stock' with Monster Upside Potential we immediately Email it to you in our detailed VIP Report so you can Beat Rest of the Crowd!!
Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way.
VipstockReports.com newsletters and website: The disclaimer is to be read entirely and fully understood before using our website, or joining our newsletter email list. Never invest into a stock discussed on this website or the Vipstockalerts.com newsletter unless you can afford to lose your entire investment. Please consult with a certified financial advisor before making any investment decisions.
VipStockReports.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your financial advisor before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies profiled on the VipstockReports.com web site and/or newsletter involve a high degree of volatility and risk, and all investors should know that they may lose a portion of or all of their investment if they decide to purchase any stocks.
Read Full Disclaimer at: http://www.vipstockreports.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)